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LipolysisIrisin is a cleaved and secreted fragment of ﬁbronectin type III domain containing 5 (FNDC5), and contributes to
the beneﬁcial effects of exercise on metabolism. Here we report the therapeutical effects of FNDC5/irisin on
metabolic derangements and insulin resistance in obesity, and show the lipolysis effect of irisin and its signal
molecular mechanism. In obesemice, lentivirus mediated-FNDC5 overexpression enhanced energy expenditure,
lipolysis and insulin sensitivity, and reduced hyperlipidemia, hyperglycemia, hyperinsulinism, blood pressure
and norepinephrine levels; it increased hormone-sensitive lipase (HSL) expression and phosphorylation, and
reduced perilipin level and adipocyte diameter in adipose tissues. Subcutaneous perfusion of irisin reduced
hyperlipidemia and hyperglycemia, and improved insulin resistance. Either FNDC5 overexpression or irisin
perfusion only induced a tendency toward a slight decrease in body weight in obese mice. In 3T3-L1 adipocytes,
irisin enhanced basal lipolysis rather than isoproterenol-induced lipolysis, whichwere prevented by inhibition of
adenylate cyclase or PKA; irisin increased the HSL and perilipin phosphorylation; it increased PKA activity, and
cAMP and HSL mRNA levels, but reduced perilipin expression. These results indicate that FNDC5/irisin
ameliorates glucose/lipid metabolic derangements and insulin resistance in obese mice, and enhances lipolysis
via cAMP–PKA–HSL/perilipin pathway. FNDC5 or irisin can be taken as an effective therapeutic strategy for
metabolic disorders.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Irisin was ﬁrstly identiﬁed in 2012 as a muscle-derived factor that
promotes the formation of brown-adipocyte-like cells in mice [1]. Irisin
is a cleaved and secreted fragment of ﬁbronectin type III domain
containing 5 (FNDC5), a type of transmembrane protein with a signal
peptide, two ﬁbronectin domains and one hydrophobic domain
inserted in the cell membrane. It is known that exercise stimulates
PGC-1a expression, which promotes FNDC5 expression, and thereby in-
creases irisin levels [1]. Cross-sectional studies revealed that circulating
irisin levels were positively correlated with biceps circumference, bodyy weight; FFA, free fatty acid;
ucose tolerance test; HFD, high
ol; ITT, insulin tolerance test;
ein 1; VAT, visceral adipose tis-
ascular Disease and Molecular
cal University, 140 Hanzhongmass index, glucose and ghrelin, but negatively with age, insulin, cho-
lesterol, and adiponectin levels in human and intrahepatic triglyceride
contents in obese adults [2–4]. Levels of irisin were signiﬁcantly higher
in participantswithmetabolic syndrome than in those without the syn-
drome [2]. An interesting question is whether long-term administration
of irisin could effectively ameliorate glucose/lipid metabolic derange-
ments, insulin resistance and obesity.
Adipose tissues play major roles in the energy homeostasis and in
the development of obesity and metabolic syndrome, which may be a
new target against obesity andmetabolic disorders [5,6]. Adipose tissue
insulin resistance and dysfunctional lipid storage in adipocytes are sen-
tinel events in the progression toward metabolic dysregulation with
obesity. Both subcutaneous adipose tissue (SAT) and visceral adipose
tissue (VAT) are linked with metabolic risk factors. VAT remains more
strongly associated with an adverse metabolic risk proﬁle even after
accounting for standard anthropometric indexes [7]. Circulating irisin
is mainly attributed to muscle secretion [1]. A recent study showed
that FNDC5/irisin was not only a myokine but also an adipokine, and
short-term periods of endurance exercise training induced FNDC5
secretion by SAT and VAT [8]. However, the effects of irisin on lipolysis
and its downstream signaling components are unknown.
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for treating genetic disorders and common multifactorial diseases by
changing the related gene expression. Lentiviral or retroviral vectors
allow the permanent integration of a therapeutic transgene in target
cells and have provided a delivery platform for several successful
clinical approaches in gene therapy. In the present study, we showed
that lentiviral vector-mediated FNDC5 overexpression effectively
ameliorated metabolic derangements and insulin resistance in high fat
diet (HFD)-induced obese mice. Persistent subcutaneous perfusion of
irisin caused similar effects to FNDC5 overexpression in obese mice.
Irisin enhances lipolysis via cAMP–PKA–hormone-sensitive lipase
(HSL)/perilipin pathway. FNDC5/irisin can be taken as an effective
therapeutic strategy for metabolic disorders.
2. Materials and methods
2.1. Mice and obesity model
Male 6-week old C57/BL6J mice were purchased from Comparative
Medicine Centre of Yangzhou University (Yangzhou, China). All of our
investigations were approved by the Experimental Animal Care and
Use Committee of Nanjing Medical University and complied with the
Guide for the Care and Use of Laboratory Animals (NIH publication,
8th edition, 2011). The mice were housed in a temperature- and
humidity-controlled room with food and tap water ad libitum and a
12-h light/12-h dark cycle. Food intake was measured daily. Body
weight (BW) was measured at weekly intervals. Mice were fed with
high fat diet (HFD, 60% kcal as fat) for 12 weeks to induce obesity.
Control mice were fed with standard diet (Ctrl, 12% kcal as fat).
2.2. Cell culture
Adipocytes were differentiated from 3T3-L1 preadipocytes (Keygen
Biotech. Co. Ltd., Nanjing, China). Brieﬂy, 3T3-L1 preadipocytes were
maintained in high glucose DMEM supplemented with 10% fetal bovine
serum (FBS), 100 units/ml penicillin G sodium, and 100 μg/ml strepto-
mycin and maintained at 37 °C in a humidiﬁed atmosphere containing
5% CO2. Two days after achieving conﬂuence, differentiation to adipo-
cytes was induced by treatment of postconﬂuent cells with 10% FBS,
10 μg/ml insulin, 1 μM dexamethasone, and 0.5 mM isobutyl-
1-methylzanthine. The differentiation medium was withdrawn 2 days
later and replaced with medium supplemented with 10% FBS and
10 μg/ml insulin. After 2 days in insulin-containing medium, the cells
were then cultured in high glucose DMEM containing 10% FBS. The
media were replaced every 2 days thereafter until 85% of the cells
contained lipid droplets. Eight days after the induction of differentiation,
3T3L1 adipocytes were ready to be used in experiments [9,10].
2.3. Construction of FNDC5 expression plasmid
Recombinant lentivirus expressing FNDC5 or EGFP vector was pur-
chased from Life Technologies (California, USA). Brieﬂy, the FNDC5
mRNA was ampliﬁed by RT-PCR, and the PCR product was inserted
into the pLenti6.3_MCS_IRES2-EGFP plasmid. The ﬁnal bicistronic plas-
mid construct, plenti-FNDC5-IRES-EGFP, was designed to co-express
the FNDC5 protein and EGFP. To produce infectious viral particles,
HEK-293 T cells cultured on 10 cm dishes were co-transfected with
the packaging mix containing pLP1, pLP2 and pLP/VSVG together with
the lentiviral plasmid (plenti-FNDC5-IRES-EGFP) using Lipofectamine
2000 (Life Technologies, California, USA). After 48 h, supernatants
were collected, cell debris was pelleted by low speed centrifugation,
and clariﬁed supernatant was removed. Viruses were concentrated by
centrifugation at 50,000 g for 2 h at 4 °C, re-suspended in opti-MEM
and stored at−80 °C. An EGFP-containing lentivirus was prepared in
parallel as a negative control.2.4. Introduction of FNDC5 plasmid
A single intravenous injection of recombinant lentivirus (1 × 108
TU/ml, 100 μl) expressing FNDC5 or EGFP vector (Life Technologies,
California, USA) was carried out at the end of the 6th week after the
diet application in Ctrl mice or HFD mice. Acute experiments were
performed 3 weeks or 6 weeks after the introduction.
2.5. Subcutaneous perfusion of irisin
Irisin (0.55 nmol/μl, 1.45 nmol/day) or saline was subcutaneously
administered with micro-osmotic pump (Model 1004, Alzet) in the
HFD mice at the end of the 8th week after diet application. The
subcutaneous perfusion site was located at midline of the lower
abdomen. Acute experiments were carried out 4 weeks after the
pump implantation.
2.6. Insulin and glucose tolerance tests
The mice were fasted for 6 h or overnight before intraperitoneal
injection with insulin (0.75 units/kg body weight) or glucose (0.9 g/kg
body weight). Blood glucose levels in the tail vein blood samples were
measured with a blood glucometer (One Touch, Johnson & Johnson,
USA) 15, 30, 60, 90 and 120 min after the injection [11].
2.7. Indirect calorimetry
The mice were individually housed for at least 3 days before the
calorimetry measurements. Metabolism parameters were simulta-
neouslymeasured in individually housedmicewith a PhenoMaster sys-
tem (TSE Systems, Thuringia, Germany). After 2 h of acclimatization, the
O2 consumption, CO2 production, heat production, and respiratory ex-
change ratio (RER) for each mouse were continuously measured for a
further 24 h. A photobeam-based monitoring system was used to
track animal movement including rearing and climbing [12].
2.8. In vitro and in vivo lipolysis
Lipolysis was performed in vitro on differentiated 3T3-L1 adipo-
cytes. Brieﬂy, cells were pre-treated without or with 1 ng/μl of irisin
for 30 min in the presence or absence of adenylate cyclase inhibitor
SQ22536 or PKA inhibitor H-89. Media were then collected for glycerol
and FFA level determinations. Lipolysis was also performed in vivo.
Brieﬂy, mice were fasted for 4 h or 24 h. Blood was collected for the
determination of plasma FFA level.
2.9. Quantitative RT-PCR analysis
Total RNAs from tissues or differentiated 3T3L1 adipocytes were
isolated using trizol and subjected to reverse transcription with
PrimeScript RT reagent (Takara Biotechnology Co., Ltd., Tokyo, Japan)
according to the manufacturer's instructions. For quantitative PCR,
cDNA fragmentswere subjected to SYBRGreen RT-PCR (Takara Biotech-
nology Co., Ltd., Tokyo, Japan) using Stepone Plus system. The quantita-
tive measures were obtained using the ΔΔCT method. Primers for all
qPCR experiments were included as follows: FNDC5: ATGAAGGAGATG
GGGAGGAA (F), GCGGCAGAAGAGAGCTATAACA (R); UCP1: ACTGCC
ACACCTCCAGTCATT (F), CTTTGCCTCACTCAGGATTGG (R); HSL: CCGT
TCCTGCAGACTCTCTC (F), CCACGCAACTCTGGGTCTAT (R); β-actin:
CTGCGTTTTACACCCTTTCTTTG (F), GCCATGCCAATGTTGTCTCTTAT (R);
Cidea: TGCTCTTCTGTATCGCCCAGT (F), GCCGTATTAAGGAATCTGCTG
(R); PGC1a: CCCTGCCATTGTTAAGACC (F), TGCTGCTGTTCCTGTTTTC
(R); PRDM16: CAGCACGGTGAAGCCATTC (F), GCGTGCATCCGCTTGTG
(R); and PPARγ: CAAAACACCAGTGTGAATTA (F), ACCATGGTAATTTCTT
GTGA (R).
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The frozen tissues or differentiated 3T3-L1 adipocytes were homog-
enized using a sonicator in ice-cold RIPA buffer containing 1% Nonidet
P-40, 0.1% SDS, and protease inhibitor. Homogenates were centrifuged
for 30 min at 12,000 rpm at 4 °C, and supernatants were collected.
Protein amounts fromall sampleswere assessed using a BCA-kit followed
by protein concentration normalization before all Western blot experi-
ments. The lysates (20–50 μg) were resolved by SDS-PAGE. Proteins
were transferred to a PVDF membrane (Bio-Rad), which was incubated
with the speciﬁc antibody (FNDC5, UCP1, HSL, P-HSL, perilipin or
P-perilipin). Blots were re-probed with the respective antibodies against
β-actin for normalization. Immunoreactive proteinswere visualizedwith
a gel imaging system (Tanon Science and Technology, Shanghai, China),
and densitometric analysis was performed with Quantity One software
(Bio-Rad).
2.11. ELISA analysis
Commercial ELISA or EIA kits were used for irisin, insulin, leptin,
cAMP, angiotensin II, norepinephrine, FFA, cholesterol, triglyceride and
glycerol. PKA activity was measured with PKA kinase activity kit (ADI-
EKS-390A, Enzo Life Sciences Inc., Farmingdale, NY, USA). Irisin kits
were bought from Phoenix Pharmaceuticals (EK-067-16, Burlingame,
USA). Minimum detectable concentration of irisin is 6.8 ng/ml. The
cross-reactivity is 100% with irisin or irisin (42–112), and 9% with
FNDC. No cross-reactivity is found with FNDC5 (165–212), FNDC5
(162–209) or irisin (42–95). The recovery is 104%, 82% and 88.7% for
spiked irisin at 5, 10 and 20 ng/ml, respectively. Intra- and inter-assay
variations are b10% and b15%, respectively. Recently, it was reported
that the interobserver and intraobserver variabilities of measurements
with the kits were 6.2% and 5.9%, respectively [13]. The serum andmus-
cle samples for measuring irisin were diluted 2 and 10 times,
respectively.
2.12. Tissue embedding and H&E staining
The mice were deeply anesthetized with isoﬂurane. Subcutaneous
adipose tissue (SAT) and visceral adipose tissue (VAT) were quickly re-
moved, rinsed in ice-cold PBS, and incubated overnight in formalin. SAT
and VATwere thenwashedwith PBS for 15min and dehydrated by suc-
cessive incubation in 70% to 100% ethanol solutions. Adipose tissues
were embedded in parafﬁn, and slices were cut every 7 mm. H&E stain-
ing was performed on adipose tissues after rehydration, and pictures
were taken with an Olympus camera mounted on an optical
microscope.
2.13. Chemicals
Antibodies against UCP1 (ab155117), FNDC5 (ab174833) and β-
actin (ab6276) were obtained from Abcam (Cambridge, England). Anti-
bodies against HSL (sc-25843) were purchased from Santa Cruz (Cali-
fornia, USA); antibodies against perilipin (#9349) and phosphorylated
HSL at Ser563 (#4139), Ser565 (#4137) and Ser660 (#4126) were pur-
chased from Cell Signaling (Massachusetts, USA). Irisin (ChinaPeptides
Co., Ltd, Shanghai, China) was derived from Escherichia coli. The puriﬁed
and identiﬁed irisin was subjected to the removal of the endotoxin with
Pierce high-capacity endotoxin removal resin (Thermo Scientiﬁc, MA,
USA). Adenylate cyclase inhibitor SQ22536 and PKA inhibitor H-89
were from Sigma (St Louis, MO). ELISA kits for insulin were obtained
from ALPCO (New Hampshire, USA); ELISA kits for leptin, cAMP, angio-
tensin II and norepinephrinewere bought fromR&Dsystems (Minneap-
olis, USA); ELISA kits for FFA was fromWako Chemicals (Osaka, Japan);
ELISA kits for cholesterol, triglyceride and glycerol were from Nanjing
Jiancheng Bioengineering Institute (Nanjing, China). Primers for all
qPCR experiments were from Life Technologies (California, USA).2.14. Statistics
Data are presented asmean± SEM, and a value of P b 0.05 was con-
sidered statistically signiﬁcant. Two-tailed, unpaired Student's t-tests
were used to compare two treatment groups. One-way ANOVA and
two-way ANOVA were used for data analysis of more than two groups
followed by Bonferroni's post-hoc analysis.
3. Results
3.1. Effectiveness of FNDC5 overexpression
FNDC5 mRNA, FNDC5 protein and irisin levels in skeletal muscle
were higher in obese mice than those in control mice. Although there
was a tendency for the serum FNDC5 and irisin levels to increase in
obese mice, this did not reach statistical signiﬁcance. Administration
of recombinant lentivirus expressing FNDC5 via tail vein increased the
FNDC5 mRNA, FNDC5 protein and irisin levels in skeletal muscle and
serum in both control and HFD mice 3 and 6 weeks after gene transfer
(Fig. 1A–C). FNDC5 gene transfer failed to cause signiﬁcant increase in
mRNA levels in the liver, SAT and VAT except in muscles (Fig. S1). The
signiﬁcant increases in the serum irisin levels and GFP ﬂuorescence in
skeletal muscle were found 1, 2, 4, and 6weeks after FNDC5 gene trans-
fer in HFD mice (Fig. S2). These results conﬁrmed the effectiveness of
the FNDC5 introduction in increasing circulating FNDC5 and irisin
levels.
3.2. FNDC5 overexpression increases energy expenditure
FNDC5 overexpression increased the O2 consumption, CO2 and heat
production in HFD mice without signiﬁcant effect on the total activity
(Fig. 2A), indicating that FNDC5/irisin increased energy expenditure.
FNDC5 overexpression had no signiﬁcant effects on body weight and
food intake in obese mice, but induced a tendency toward a slight de-
crease in body weight (−4.3% vs. vehicle at the end of the 6th weeks
after the gene transfer, P=0.288) in obesemice (Fig. 2B,C). Intraperito-
neal injection of irisin had no signiﬁcant effect on core temperature in
obese mice (Fig. S3), suggesting that circulating irisin does not alter
the central setpoint of body temperature. The increased heat production
effect on body temperature may be offset by increased heat dissipation
due to the mechanisms of body temperature regulation.
3.3. FNDC5 overexpression improves lipid metabolism
Serum cholesterol, triglyceride and free fatty acid (FFA) levels were
increased in HFD mice, which were reduced by FNDC5 overexpression,
indicating that FNDC5/irisin effectively attenuated the disturbance of
lipidmetabolism in obesity (Fig. 3A). FNDC5 overexpression had no sig-
niﬁcant effect on the increased serum leptin level in HFD mice (Fig. 3B).
3.4. FNDC5 overexpression improves glucose metabolism and insulin
resistance
The fasting blood glucose and serum insulin levels were increased in
HFD mice, which were reduced by FNDC5 overexpression (Fig. 3C,F).
Glucose tolerance test (GTT) and insulin tolerance test (ITT) are often
used to evaluate insulin resistance. HFD mice manifested signiﬁcantly
elevated glucose excursions following glucose challenge compared
with control mice in the GTT, and the glucose excursion was reduced
by FNDC5 overexpression (Fig. 3D). The efﬁciency of insulin was quan-
tiﬁed by its ability in reducing blood glucose level in the ITT. Insulin was
less effective in HFD mice than that in control mice, which were
prevented by FNDC5 overexpression (Fig. 3E). Akt is known to mediate
the effects of insulin on glucose metabolism. FNDC5 overexpression
promotes the Akt phosphorylation in both control and HFD mice
Fig. 1. Effects of FNDC5 overexpression on FNDC5 and irisin levels in skeletalmuscle and serumof Ctrl andHFDmice 3 and 6weeks after gene transfer. A, FNDC5mRNA, FNDC5protein and
irisin protein in skeletalmuscle; B, representative photos ofWesternblot show the FNDC5 protein in skeletalmuscle; C, FNDC5 protein and irisin protein in serum. Values aremean±SEM.
*P b 0.05 vs. Vector with same diet. †P b 0.05 vs. Ctrl with same treatment. n = 6 for each group.
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metabolism and insulin resistance in obesity.
3.5. FNDC5 overexpression reduces blood pressure
Obesity is known to be amarker of cardiovascular risk, and is an im-
portant and primary contributor to the pathophysiology of hyperten-
sion [14]. Increased afferent activity from the white adipose tissue
(WAT) and enhanced adipose afferent reﬂex are involved in sympathet-
ic activation and hypertension in HFD-induced obesity rats [15,16]. HFD
mice showed an increased serum norepinephrine level (an index of
sympathetic activity) and a tendency of increased blood pressure.
FNDC5 overexpression signiﬁcantly reduced blood pressure (Fig. S5)
and serum norepinephrine level in obese mice, but had no signiﬁcant
effect on serum angiotensin II level (Fig. 3G). These results indicate
that FNDC5/irisin plays a beneﬁcial role in attenuating hypertension
and sympathetic activation in obesity.Fig. 2. Effects of FNDC5 overexpression on energymetabolism, bodyweight and food intake in C
in 24h at the end of the 6thweeks after gene transfer; B, bodyweight. C, accumulated food intak
diet. †P b 0.05 vs. Ctrl with same treatment. n = 12 for each group.3.6. FNDC5 overexpression increases UCP1 expression
UCP1 is the key protein to the thermogenic capacity of adipose
tissues, which enables the separation of lipid oxidation from ATP
production, allowing a higher metabolic rate and the conversion of
nutritional energy to heat [17,18]. Irisin acts on white adipose cells
in vitro and in vivo to stimulate UCP1 expression and causes a broad
program of brown-fat-like development [1,19]. The present study
showed that FNDC5 overexpression signiﬁcantly increased UCP1
mRNA and protein expression in the SAT but not in the VAT in both
control and HFD mice (Fig. 4A,F). The UCP1 protein level in brown
adipose tissues (BAT) was much higher than that in SAT and VAT, but
FNDC5 overexpression failed to cause a signiﬁcant increase in UCP1
protein in the BAT (Fig. S6). Moreover, the mRNA levels of other
brown fat genes were measured. It was found that FNDC5 overexpres-
sion caused a mild increase in PGC1α mRNA in SAT, but not in Cidea,
Prdm16 and PPARγmRNA (Fig. S7).trlmice andHFDmice. A, O2 consumption, CO2 and heat production, and total body activity
e of 6weeks after the gene transfer. Values aremean±SEM. *P b 0.05 vs. Vectorwith same
Fig. 3.Effects of FNDC5 overexpression on lipid/glucosemetabolism, insulin sensitivity and lipolysis in Ctrlmice andHFDmice6weeks after gene transfer. A, serum cholesterol, triglyceride
and free fatty acid (FFA) levels; B, serum leptin level; C, fasting blood glucose; D, glucose tolerance test (GTT); E, insulin tolerance test (ITT); F, serum insulin level; G, serum angiotensin II
and norepinephrine levels; H, lipolysis effects represented with serum FFA levels after 4 h and 24 h fasting. Values are mean ± SEM. *P b 0.05 vs. Vector with same diet. †P b 0.05 vs. Ctrl
with same treatment. n = 6 for each group.
Fig. 4. Effects of FNDC5 overexpression onUCP1, perillipin andHSL expressions, HSL phosphorylation and adipocyte diameter in SAT and VAT of Ctrlmice andHFDmice 6weeks after gene
transfer; A, relative values of UCP1 mRNA and protein; B, relative values of perillipin; C, relative values of HSL mRNA; D, phosphorylated HSL; E, adipocyte diameter; F, representative
photos of Western blot show the perillipin, UCP1, P-HSL (Ser563, Ser565, Ser 660) and HSL proteins. Values are mean ± SEM. *P b 0.05 vs. Vector with same diet. †P b 0.05 vs. Ctrl with
same treatment. n = 3 for each group in A–D; n = 6 for each group in E.
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cytes in SAT
FNDC5 overexpression increased the plasma FFA levels after 4-h or
24-h fasting in obese mice (Fig. 3H), suggesting that FNDC5/irisin
enhances the fasting-induced lipolysis. The diameter of adipocytes
was increased in both SAT and VAT of HFDmice. FNDC5 overexpression
reduced the adipocyte size in SAT of HFD mice (Figs. 4E, S8) and atten-
uated the fat accumulation in the liver of HFD mice (Fig. S9).
3.8. FNDC5 overexpression enhanced lipolysis via cAMP–PKA–perilipin/HSL
pathway
There is no signiﬁcant difference of perilipin levels in both SAT and
VAT between control and HFD mice, while FNDC5 overexpression
reduced the perilipin levels in both SAT and VAT (Fig. 4B,F). The HSL
mRNA and phosphorylated HSL at Ser660 in both SAT and VAT were
increased in HFD mice. FNDC5 overexpression increased HSL mRNA
and the phosphorylated HSL at Ser563 and Ser660 but not at Ser565
in the SAT and VAT in both control and HFD mice (Fig. 4C,D,F).
3.9. Persistent perfusion of irisin improves lipid metabolism and insulin
resistance
Persistent subcutaneous perfusion of irisin with micro-osmotic
pump for 4 weeks had no signiﬁcant effects on body weight and food
intake in obese mice, but a tendency toward a slight decrease in body
weight (−4.0% vs. saline at the end of the 4th weeks, P = 0.486) was
induced by irisin perfusion in obese mice (Fig. 5A,B). Similar to FNDC5
overexpression, irisin perfusion reduced serum cholesterol, triglyceride
and FFA levels, as well as fasting blood glucose level in HFD mice
(Fig. 5C,D). GTT and ITT showed that irisin perfusion improved insulin
sensitivity in HFD mice (Fig. 5E). The serum irisin level in the mice
perfused with irisin was about three times higher than that with saline
(Fig. 5F). On the other hand, irisin infusion increased UCP1 mRNA and
protein expression in SAT (Fig. S10).Fig. 5. Effects of subcutaneous perfusion of irisinwithmicro-osmotic pump for 4weeks on body
HFDmice. A, bodyweight; B, food intake; C, serum cholesterol, triglyceride and free fatty acid (FF
(ITT); F, serum irisin levels. Values are mean ± SEM. *P b 0.05 vs. Saline. n = 6 for each group3.10. Irisin enhances lipolysis via cAMP–PKA–HSL/perilipin pathway
in vitro
In 3T3-L1 adipocytes, irisin concentration-dependently enhanced
basal lipolysis, reaching its maximal effect at about 1 h after the irisin
treatment. However, irisin had no signiﬁcant effect on isoproterenol
(ISO)-induced lipolysis (Fig. 6A,B). The lipolysis effect of irisin was
prevented by adenylate cyclase inhibitor SQ22536 or PKA inhibitor
H-89 (Fig. 6C). Irisin caused similar increase in cAMP levels and PKA
activity to ISO or ISO plus irisin (Fig. 6D). On the other hand, irisin
increased the phosphorylation of HSL at Ser563 or Ser660 but not at
Ser565 as well as the phosphorylation of perilipin at Ser522 (Fig. 7A,C);
it increased HSL mRNA level but reduced perilipin level (Fig. 7B,D).
3.11. Irisin enhances UCP1 mRNA and Akt phosphorylation in vitro
To deﬁne the timeframe of irisin in inducing the browning of white
adipocytes, we examined the effects of irisin on the UCP1 mRNA in
3T3L1 adipocytes administered during the differentiation and after the
differentiation period, respectively. Irisin increased the UCP1 mRNA in
differentiated 3T3L1 adipocytes. Irisin given during the differentiation
period caused a greater effect on the UCP1 mRNA than that given after
the differentiation (Fig. S11). Irisin caused a similar level of Akt
phosphorylation with insulin in 3T3-L1 adipocytes (Fig. S12).
4. Discussion
This study shows that systemic delivery of lentivirus expressing
FNDC5 reduces blood glucose level, improves insulin resistance, and
increases UCP1 expression and energy expenditure in obese mice. Per-
sistent subcutaneous infusion of irisin causes similar effects to FNDC5
overexpression in obese mice. More important novel ﬁndings in this
study are that FNDC5/irisin in obese mice attenuates hyperlipidemia
and enhances lipolysis via cAMP–PKA–HSL/perilipin pathway. It
increases HSL expression and phosphorylation, and reduces perilipin
level and adipocyte diameter in adipose tissues in obese mice. Theweight, food intake, lipid/glucosemetabolism, insulin sensitivity and serum irisin levels in
A) levels; D, fasting blood glucose; E, glucose tolerance test (GTT) and insulin tolerance test
.
Fig. 6. Effects of irisin on lipolysis and its downstream signalmolecules in 3T3L1 adipocytes. A, time effect of irisin on the basal lipolysis and isoproterenol (ISO)-induced lipolysis. *P b 0.05
vs. the values before irisin, †P b 0.05 vs. Basal; B, dose effect of irisin on the basal lipolysis and ISO-induced lipolysis. *P b 0.05 vs. the values without irisin treatment, †P b 0.05 vs. Basal; C,
effects of vehicle (Veh), adenylate cyclase inhibitor SQ22536 and PKA inhibitor H-89 on the lipolysis response to irisin; D, effects of PBS, irisin and ISO on the cAMP levels and relative PKA
activity. *P b 0.05 vs. PBS + PBS, †P b 0.05 vs. PBS + Irisin. Values are mean ± SEM. n = 6 for each group.
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FNDC5/irisin ameliorates metabolic derangements and insulin resis-
tance in obesity. FNDC5/irisin can be taken as an effectively therapeutic
strategy for glucose/lipid metabolic disorders. In addition, FNDC5
overexpression decreased serum norepinephrine level and blood
pressure in obese mice, suggesting an important role in preventing
obesity-related sympathetic activation and hypertension.
FNDC5 overexpression enhanced the rising plasma FFA response to
fasting in obese mice, and irisin enhanced glycerol and FFA levels in
cultured 3T3-L1 adipocytes. The results indicate that irisin promotes
lipolysis in vitro and in vivo, which may be an important mechanism
for the therapeutic roles of irisin in attenuating the disturbance of
glucose/lipid metabolism and insulin resistance. Therefore, the down-
stream signal pathway of irisin in promoting lipolysis was investigated
in obese mice and in 3T3-L1 adipocytes.Fig. 7. Effects of irisin on HSL and perilipin phosphorylation and expressions in 3T3L1 adipocyte
perilipin protein level. HSL and perilipin phosphorylation was examined 0.5 h after administra
administration of vehicle or irisin. Values are mean ± SEM. n = 3 for each group. *P b 0.05 vs.Perilipin is a protein that coats the lipid droplets in adipocytes and
acts as a protective coating fromHSL. Perilipin phosphorylation exposes
the stored lipids to HSL and then promotes lipolysis [20–22]. PKA-
mediated phosphorylation of perilipin is required for inducing the
translocation of HSL from the cytosol to the lipid droplets to initiate
lipolysis [23,24]. It is known that activation of β-adrenergic receptors
stimulates lipolysis via cAMP-dependent PKA activation in fat cells.
HSL is important for thedegradation of triacylglycerol in adipose tissues.
The phosphorylation at HSL Ser563 or Ser660 activates HSL and lipoly-
sis, while phosphorylation at HSL Ser565 prevents HSL activation [25].
The ﬁndings in the present study indicate that FNDC5/irisin promotes
lipolysis, which is mediated by cAMP-dependent PKA activation and
the phosphorylation of HSL and perilipin. Irisin-induced perilipin
down-regulation and HSL up-regulation partially contribute to its
lipolysis-promoting effect. It is noted that irisin enhanced basal lipolysiss. A, phosphorylation of HSL; B, HSL mRNA expression; C, phosphorylation of perilipin; D,
tion of vehicle or irisin; HSL mRNA and perilipin protein levels were measured 24 h after
Veh.
1874 X.-Q. Xiong et al. / Biochimica et Biophysica Acta 1852 (2015) 1867–1875but not ISO-induced lipolysis, and caused similar increase in cAMP
levels and PKA activity to ISO or ISO plus irisin, possibly because irisin
shares its downstream cAMP–PKA pathway with ISO.
Recent evidence has revealed several biological and genetic
differences between VAT and SAT [26]. Such differences are reﬂected
in their contrasting roles in the pathogenesis of obesity-related
cardiovascular and metabolic problems [27]. It has been found that
either SAT or VAT was strongly correlated with insulin resistance in
African Americans [28]. Although the VAT is more strongly associated
with an adverse metabolic risk, both SAT and VAT are correlated with
metabolic risk factors [7]. UCP1 is a transmembrane protein that de-
creases the proton gradient generated in oxidative phosphorylation.
UCP1-mediated heat generation in adipocytes uncouples the respirato-
ry chain, allowing for fast substrate oxidation with a low rate of ATP
production [29,30]. It is known that irisin stimulates UCP1 expression
and brown-fat-like development [1,31]. We found that FNDC5 overex-
pression signiﬁcantly increased UCP1 mRNA and protein expressions,
and reduced the adipocyte diameter in the SAT but not in the VAT in
both control andHFDmice. Irisin increasedUCP1mRNA in 3T3L1 adipo-
cytes. These results suggest that SAT is more sensitive to FNDC5/irisin
than VAT in the effects on brown-fat-like development and heat
production.
FNDC5 overexpression increased oxygen consumption, carbon
dioxide and heat production in obese mice but did not signiﬁcantly
affect the total activity and food intake. There seems to be two crucialFig. 8. Schematic diagram showing FNDC5 overexpression or irisin prevents glucose/lipid meta
enhanced lipolysis and the uncoupling of oxidative phosphorylation. Irisin induces the phosp
Perilipin is a protein localized on the surface of lipid droplets that serves as a gatekeeper and inh
ylation of perilipin induces the translocation of HSL from the cytosol to the surface of lipid dropl
down-regulation of perilipin and up-regulation of HSL promote the lipolysis. On the other hand
of oxidative phosphorylation in mitochondria, and increases the heat production and energy ereasons for the increased energy expenditure. One is that FNDC5/irisin
induced enhancement in lipolysis via cAMP–PKA–HSL/perilipin
pathway. Another reason is that FNDC5/irisin induced more heat
generation due to the increased UCP1 expression which causes a fast
substrate oxidation with a low rate of ATP production (Fig. 8). The in-
creased lipolysis, UCP1 expression and energy expenditure contribute
to the beneﬁcial effects of FNDC5/irisin on attenuating glucose/lipid
metabolic derangements and insulin resistance in obesity. It is known
that the PI3K–Akt pathway primarily mediates the effects of insulin on
glucose metabolism [32]. We found that FNDC5 overexpression
promotes the Akt phosphorylation in both control and HFD mice. Irisin
caused a similar level of Akt phosphorylation with insulin in 3T3-L1
adipocytes. These results suggest that irisin-induced Akt activation
may improve glucose metabolism, which may partially contribute to
the improved insulin sensitivity in mice with FNDC5 overexpression
or irisin infusion. Bariatric surgery has been shown to be an effective
and durable therapy for the treatment of morbid obese patients [33,
34]. In this study, FNDC5/irisin promoted lipolysis and reduced lipid in
adipocytes and hepatocytes. The lipolysis effect of irisin may play
beneﬁcial metabolic roles in reducing the lipid accumulation in tissues,
decreasing serum lipid levels and preventing obesity.
It is unexpected that irisin had no signiﬁcant role in reducing body
weight in obese mice regardless of striking effect on lipolysis. We
noted that irisin induced a tendency in increasing food intake and in
reducing body weight in obese mice. It is possible that the role of irisinbolic derangements, improves insulin resistance and increases energy expenditure via the
horylation of both hormone-sensitive lipase (HSL) and perilipin via cAMP/PKA pathway.
ibits lipolysis. The phosphorylation of HSL causes the activation of HSL, and the phosphor-
ets for converting stored triglycerides to glycerol and free fatty acids (FFAs). Irisin-induced
, irisin increases the uncoupling protein 1 (UCP1) expression, which causes the uncoupling
xpenditure. P, phosphorylation; +, promoting effect.
1875X.-Q. Xiong et al. / Biochimica et Biophysica Acta 1852 (2015) 1867–1875in reducing body weight is offset by a compensatory slight increase in
food intake. The irisin-induced tendency of slight increase in food intake
in obesitymay be attributed to the up-regulated setpoint in the brain for
energy balance and body weight control [35–37]. Interestingly, the
effects of irisin in improving the glucose/lipid metabolic derangements
are beneﬁcial to the whole body in obesity or metabolic syndrome. A
main limitation in the present study is that we have not explored
what happens to all the lipolyzed fat, which is worthy of further studies.
5. Conclusion
FNDC5 overexpression or persistent subcutaneous perfusion of irisin
increased energy expenditure, ameliorated glucose/lipid metabolic de-
rangements, and attenuated insulin resistance in HFD-induced obese
mice. FNDC5/irisin enhanced lipolysis via cAMP–PKA–HSL/perilipin
pathway. Irisin increased HSL and UCP1 expressions as well as HSL
phosphorylation. It increased perilipin phosphorylation but reduced
perilipin expression. These effects contribute to the increased energy
expenditure in obesity. FNDC5/irisin can be used as an effective strategy
in attenuatingmetabolic derangements and insulin resistance in obesity
and diabetes.
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